pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
Sep 25, 26
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
Sep 25, 26
STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
stat
Sep 25, 26
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
Sep 25, 26
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Sep 25, 26
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
Sep 24, 26
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
Sep 24, 26
The FDA’s Overton era, and dispatches from Shanghai
stat
Sep 24, 26
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
Sep 24, 26
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
Sep 24, 26
STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
stat
Sep 24, 26
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
Sep 24, 26
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
Sep 24, 26
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
Sep 24, 26
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
Sep 23, 26
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
Sep 23, 26
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
Sep 23, 26
STAT+: Flagship gets a Pentagon contract
stat
Sep 23, 26
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
Sep 23, 26
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
Sep 23, 26
Enveda reaps $311M series E to feed ambition to become a ‘household name’
fiercebiotech
Sep 23, 26
Opinion: Mentally ill women deserve more support to have children
stat
Sep 22, 26
STAT+: HHS unveils new initiatives to reduce animal testing in drug development
stat
Sep 22, 26
STAT+: Did the Trump administration just cut Novo a huge financial win?
stat
Sep 22, 26
Viking shares surge on updated obesity drug data
biopharma dive
Sep 22, 26
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 22, 26
Viking touts once-a-month weight loss maintenance data
endpoints
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 22, 26
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
← prev
page 9 of 25
next →